Webinar: Equity Liquidation After IPO Analysis

A common practice across universities that hold equity in a company that IPOs is to sell all of its shares as soon as the lock up expires. But do the best returns necessarily come from selling all your stock immediately? When is the right time to sell stock in a therapeutics company?

Webinar: 2019 Midyear Financing Trends

It’s Spring, which means it is once again time for OUP’s annual financing trends webinar. Which sectors have had the greatest amounts of investment and which are facing funding challenges? How do these trends apply to advancing academic technologies? What does the beginning of 2019 imply for the rest of the year and what lies over the horizon?

Webinar: Small Molecule vs Antibody Development Challenges

Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?

Webinar: Venture Capital & University Startup Financial Trends of 2018

We’re almost halfway through 2018, which means it is once again time for OUP’s annual financing trends webinar. Which sectors have had the greatest investment and which are facing funding challenges? How do these trends apply to advancing academic technologies? What does the beginning of 2018 imply for the rest of the year and what lies over the horizon?

Webinar: University In House Therapeutics Development

Recently, several universities and research institutions have set up internally driven and funded therapeutics development programs providing faculty the opportunity to push high impact translational research projects further than has been typically seen within an academic setting. These programs can oversee all stages of therapeutic discovery and development, from lab-based discovery to clinical trials. Why did these institutions decide to start these programs? How are these programs administered? What multi-disciplinary talent is needed and where did each institution find it? And perhaps most importantly, how much do these programs cost and who pays the bill?

Webinar: 2017 Midyear Startup Financing Trends

So we’re halfway through 2017. What’s the pulse on midyear VC investment? Which sectors are facing funding challenges, and which are flushed with cash? How does this apply to advancing university technologies?